With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Eli Lilly says GIP/GLP-1 agonist tirzepatide can reduce the risk of diabetes in overweight, obese people with prediabetes.

Treatment with tirzepatide reduced the risk of heart failure outcomes – specifically a heart failure urgent visit or hospitalisation, oral diuretic intensification, or cardiovascular death ...